📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Banka BioLoo Q3 FY26: Revenue Up 15% YoY, EBITDA Turns Positive at ₹90 Lakhs
Banka BioLoo reported a 15% YoY growth in standalone gross sales revenue to ₹18.78 crore for Q3 FY26. The company achieved a significant operational turnaround with standalone EBITDA rising to ₹90 lakh from a loss of ₹33.6 lakh in the previous year, driven by cost optimization and increased execution in the WaSH segment. While the company still reported a consolidated net loss of ₹12.45 lakh, it is a substantial improvement from the ₹145.54 lakh loss in Q3 FY25. The total unexecuted order book remains robust at ₹113 crore, providing strong revenue visibility.
Key Highlights
Standalone Gross Sales Revenue increased by 15% YoY to ₹18.78 crore in Q3 FY26.
Standalone EBITDA turned positive at ₹90 lakh, reflecting a ~373% increase from the previous year's loss.
Total unexecuted order book stands at ₹113 crore, split between Railways (₹49.5 cr) and WaSH (₹63.5 cr).
New order wins in the WaSH segment totaled ₹14.64 crore during Q3, including expansion into Mumbai and Bangalore.
Consolidated net loss narrowed significantly to ₹12.45 lakh from ₹145.54 lakh in the same quarter last year.
💼 Action for Investors
Investors should monitor the company's ability to maintain EBITDA margins as it executes its ₹113 crore order book. The shift towards the WaSH segment and expansion into new geographies like Mumbai and Bangalore are positive indicators for long-term growth.
Banka BioLoo Q3 FY26: Revenue Grows to ₹15.93 Cr, Net Loss Narrows Significantly to ₹0.22 Cr
Banka BioLoo reported a revenue of ₹15.93 crore for Q3 FY26, up from ₹14.19 crore in the same quarter last year. The company significantly narrowed its net loss to ₹0.22 crore from a loss of ₹1.46 crore YoY, indicating improved operational efficiency. Total expenses for the quarter stood at ₹16.22 crore, with material costs being the largest component at ₹5.71 crore. While the company remains loss-making on a nine-month basis with a loss of ₹1.19 crore, the quarterly trend shows a strong recovery toward break-even.
Key Highlights
Revenue from operations increased by 12.3% YoY to ₹15.93 crore from ₹14.19 crore
Quarterly net loss narrowed by 85% YoY to ₹0.22 crore compared to ₹1.46 crore
Nine-month total income reached ₹42.88 crore, showing steady growth over the previous year
Earnings Per Share (EPS) improved to (0.20) for the quarter, up from (1.35) in Q3 FY25
Finance costs for the quarter were ₹0.66 crore, showing a slight decrease from ₹0.72 crore YoY
💼 Action for Investors
The narrowing of losses and steady revenue growth are encouraging signs of a potential turnaround. Investors should monitor the company's ability to achieve net profitability in the upcoming quarters before increasing exposure.
Banka BioLoo Q3 Results: Revenue Up 12% YoY to ₹15.93 Cr, Net Loss Narrows to ₹0.22 Cr
Banka BioLoo reported a standalone revenue of ₹15.93 crore for the quarter ended December 31, 2025, marking a 12.3% increase from ₹14.19 crore in the same period last year. The company significantly narrowed its net loss to ₹0.22 crore, compared to a loss of ₹1.46 crore in Q3 FY25 and ₹1.10 crore in the preceding quarter. For the nine-month period, revenue grew to ₹42.73 crore, while the net loss reduced sharply to ₹1.19 crore from ₹7.57 crore in the previous year. This performance indicates a strong recovery trend and improved operational efficiency.
Key Highlights
Standalone revenue for Q3 FY26 grew 12.3% YoY to ₹15.93 crore from ₹14.19 crore.
Net loss narrowed significantly to ₹22.01 lakhs from ₹146.45 lakhs in the year-ago quarter.
9-month standalone revenue reached ₹42.73 crore, up from ₹40.92 crore in 9M FY25.
9-month net loss reduced to ₹1.19 crore compared to a substantial loss of ₹7.57 crore in the previous year.
Total expenses for the quarter stood at ₹16.22 crore, slightly higher than ₹15.82 crore in Q3 FY25.
💼 Action for Investors
The consistent narrowing of losses and steady revenue growth suggest a potential turnaround for the company. Investors should watch for the company to achieve break-even and sustained profitability in the upcoming quarters before increasing exposure.